169883-33-4

Basic information

• Product Name: 2-(4-amino-3-bromophenyl)ethan-1-ol
• Synonyms: 2-(4-amino-3-bromophenyl)ethan-1-ol
• CAS NO: 169883-33-4
• Molecular Weight: 216.077
• Mol File: 169883-33-4.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 2-(4-amino-3-bromophenyl)ethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-amino-3-bromophenyl)ethan-1-ol(169883-33-4)
• EPA Substance Registry System: 2-(4-amino-3-bromophenyl)ethan-1-ol(169883-33-4)

Safety Data

• Hazardous Substances Data: 169883-33-4(Hazardous Substances Data)

Upstream product

• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 
• 100-27-6 2-(4-nitrophenyl)ethanol 
• 75178-16-4 2-(4-Acetamidophenyl)ethyl acetate 

Downstream Products

• 197723-46-9 2-[3-Bromo-4-(pyrrolidin-1-ylazo)-phenyl]-ethanol 
• 250160-62-4 2-[3-bromo-4-(pyrrolidin-1-ylazo)-phenyl]-ethanol 
• 197723-38-9 (11R,14S)-11-(3-Iodo-4-methoxy-phenyl)-9,12-dioxo-4-(pyrrolidin-1-ylazo)-2-oxa-10,13-diaza-tricyclo[14.2.2.1^3,7]henicosa-1⁽¹⁹⁾,3,5,7⁽²¹⁾,16⁽²⁰⁾,17-hexaene-14-carboxylic acid methyl ester 
• 250160-63-5 [3-bromo-4-(pyrrolidin-1-ylazo)-phenyl]-acetic acid 
• 250160-64-6 (S)-2-[(R)-2-{2-[3-Bromo-4-(pyrrolidin-1-ylazo)-phenyl]-acetylamino}-2-(3-iodo-4-methoxy-phenyl)-acetylamino]-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 197723-34-5 [3-Bromo-4-(pyrrolidin-1-ylazo)-phenyl]-acetic acid 
• 197723-36-7 (S)-2-[(R)-2-{2-[3-Bromo-4-(pyrrolidin-1-ylazo)-phenyl]-acetylamino}-2-(3-iodo-4-methoxy-phenyl)-acetylamino]-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 1420011-27-3 C₁₀H₁₂BrNO₂ 
• 1420009-17-1 C₂₇H₄₂BrNO₃Si 
• 1420011-89-7 C₂₇H₃₂BrNO₃ 
• 1420012-02-7 C₂₃H₃₄BrNO₃Si 
• 1420012-09-4 C₂₇H₄₄BrNO₂Si 
• 1420009-32-0 C₂₇H₃₁NO₃ 
• 1420011-82-0 C₂₅H₄₀BrNO₂Si 

Relevant articles and documents

SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4

The present invention relates to novel quinazolinone derivatives of formula (I) as well as pharmaceutical compositions containing these compounds. The compounds of formula (I) as provided herein can act as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4), and can thus be used as therapeutic agents, particularly in the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions or conditions which can be affected by alteration of glutamate level or signalling.

A Pd(0)-mediated indole (macro)cyclization reaction

Herein we report a systematic study of the Larock indole annulation designed to explore the scope and define the generality of its use in macrocyclization reactions, its use in directly accessing the chloropeptin I versus II DEF ring system as well as key

Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors

Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.